Journal article
Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors
KH Gartlan, JK Jaiswal, MR Bull, H Akhlaghi, VR Sutton, KA Alexander, K Chang, GR Hill, CK Miller, PD O'Connor, J Jose, JA Trapani, SA Charman, JA Spicer, SMF Jamieson
ACS Pharmacology and Translational Science | Published : 2022
Abstract
Perforin is a key effector of lymphocyte-mediated cell death pathways and contributes to transplant rejection of immunologically mismatched grafts. We have developed a novel series of benzenesulfonamide (BZS) inhibitors of perforin that can mitigate graft rejection during allogeneic bone marrow/stem cell transplantation. Eight such perforin inhibitors were tested for their murine pharmacokinetics, plasma protein binding, and their ability to block perforin-mediated lysis in vitro and to block the rejection of major histocompatibility complex (MHC)-mismatched mouse bone marrow cells. All compounds showed >99% binding to plasma proteins and demonstrated perforin inhibitory activity in vitro an..
View full abstractGrants
Awarded by Wellcome Trust
Funding Acknowledgements
This work was supported by the Wellcome Trust (Grants 092717 and 107591/Z/5/Z) and the Cancer Society Auckland Northland (New Zealand). The authors also acknowledge Dr. David Middlemiss for his invaluable contribution to this project.